Documents

Filter documents Clear search

pdf icon

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

File size: 320kb | Date: 1 September 2018 | Clinical Statements - PDF

A Danish database study suggests that children born to women who have used hormonal contraception (HC) in the three months prior to conception or in early pregnancy are at increased risk of developing childhood non-lymphoid leukaemia compared with children whose mothers have never used HC. The FSRH CEU provides a critical appraisal of the study in this statement.

pdf icon

FSRH CEU Statement: Contraception for Women with Eating Disorders (May 2018)

File size: 366kb | Date: 1 May 2018 | Clinical Statements - PDF

Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.

pdf icon

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

File size: 127kb | Date: 1 March 2018 | Clinical Statements - PDF

Much recent media attention has been given to the subject of a potential association between hormonal contraception and depression. The FSRH CEU monitors and reports relevant emerging evidence. A new systematic review published in Contraception examines the existing evidence relating to risk of depression associated with use of progestogen-only contraception (POC).1 The authors of the review conclude that the bulk of the evidence does not support an association between use of POC and depression based on validated measures. Meta-analysis was not possible due to the heterogeneity of studies.

pdf icon

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids (February 2018)

File size: 225kb | Date: 1 February 2018 | Clinical Statements - PDF

The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002902.jsp&mid=WC0b01ac058004d5c1

pdf icon

FSRH CEU Statement: Response to Study: Intrauterine Contraception Use and Cervical Cancer Risk (January 2018)

File size: 139kb | Date: 1 January 2018 | Clinical Statements - PDF

This statement responds to a recent study that reported that women who had used intrauterine contraception (IUC) were over one third less likely to experience invasive cervical cancer than women who had not used IUC. The study has received media attention and the FSRH CEU considered it important to put the findings into perspective. January 2018

pdf icon

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

File size: 472kb | Date: 1 December 2017 | Clinical Statements - PDF

FSRH's Clinical Effectiveness Unit (CEU) reviews an observational study published in the New England Journal of Medicine. The study reports that, in the Danish study population, women who were currently using any method of hormonal contraception* (HC) or had done so within the last 6 months were 20% more likely to be diagnosed with breast cancer than those who had never used HC.